Abstracts of the 24 th National Congress of Digestive Diseases / Digestive and Liver Disease 50/S2 (2018) e63–e238 e223 P.09.18 DIETARY INTAKE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: QUALITATIVE AND QUANTITATIVE EVALUATION G.G. Caprio * , M. Dallio, A.G. Gravina, R. Di Sarno, C. Loguercio, A. Federico Hepatogastroenterology Division, University of Campania “Luigi Vanvitelli”, Naples, Italy Background and aim: There are very few reports about the intake of nutrients for the development or progression of non-alcoholic steatohepatitis (NASH). The individual roles of various nutritional and metabolic factors in the pathogenesis and natural history of NAFLD are still incompletely understood. The aim of this study was to identify the dietary habits and the nutrient intake in patients with NASH, in comparison to chronic hepatitis C (HCV)-related patients. Material and methods: We prospectively evaluated the intake of macronutrients and micronutrients in 124 NAFLD and 162 HCV patients, compared to 2326 subjects as a control group. The food intake of a complete week was recorded by each subject using a weekly dietary diary. These were converted to nutrient and food intake data using the Winfood Software 2.0 package (Medimatica s.r.l., Martinsicuro, Italy). Results: We noticed major differences in macro- and micronutrients intakes in NASH and HCV patients compared to controls. Proteins, carbohydrate (glucose, fructose, sucrose, maltose and amide), sat- urated fatty acid (SFA), monounsaturated fatty acid (MUFA), folic acid, vitamin A and C (p<0.0001), and thiamine (p<0.0003) in- gestion was found to be higher in patients with NASH, while total lipids, polyunsaturated fatty acid (PUFA), riboflavin and vitamin B6 daily intake were lower compared to controls (p<0.0001). Similarly, NASH patients had significantly reduced carbohydrate intake (p<0.0001) and an increased intake of calcium (p<0.0001) compared to HCV positive patients. Finally, we showed in NASH males an increase in the intake of SFA, PUFA, soluble carbohydrates (p<0.0001) and a decrease in the amount of fiber (p<0.0001) compared to control males. In NASH female population, we showed an increase of daily total calories, SFA, MUFA, soluble carbohydrates, starch and vitamin D ingested (p<0.0001) with a reduction of fibers and calcium (p<0.0001) compared to control females. Conclusions: This study showed how NASH patients’ diets, in both male and females, is affected by a profound alteration in macro- and micronutrients intake, and this could be one of the key factors involved in maintaining the metabolic homeostasis necessary for the development of this pathology. P.09.19 RADIOEMBOLIZATION WITH YTTRIUM-90 MICROSPHERES IN HEPATOCELLULAR CARCINOMA: AN ITALIAN EXPERIENCE A. Massella * , G. Taddei, G. Carbognin, E. Oliboni, M. Salgarello, F. Severi, M. Cirillo, P. Bocus, A. Masotto Ospedale Sacro Cuore Don Calabria, Negrar (VR), Italy Background and aim: Hepatocellular carcinoma (HCC) is a com- mon cause of worldwide mortality. In the last years, transarterial radioembolization (TARE) with Yttrium-90 microspheres has been proposed for both intermediate HCC poorly responsive to transar- terial chemoembolization (TACE) and locally-advanced HCC with segmental or lobar portal vein thrombosis (PVT). The study aim was to evaluate efficacy and safety of TARE in HCC patients. Material and methods: From January 2016 to October 2017 18 consecutive patients (M=17, F=1, median age 73 [24–85] years) with HCC were selected for TARE by the multidisciplinary HCC board. TARE was performed using 90Y glass microspheres. Tumor response was assessed using computed tomography or magnetic resonance at 3 months evaluated according to modified Response Evaluation Criteria in Solid Tumor. Results: Among 18 patients treated with TARE, 10 (55.6%) had intermediate and 8 (44.4%) advanced stage HCC. HCCs were firstly diagnosed 18 (range 2–96) months before TARE. All patients except one underwent previous treatments for HCC (median number of treatments 2, range 1–6). Other baseline features were: aetiology: hepatitis virus in 4 (22.2%), alcohol in 5 (27.8%), multiple in 9 (50%); Child-Pugh class A in 15 (83.3%), B7 in 3 (16.7%); MELD score 7.5 (range 2–14); pathologic type: unifocal in 7 (38.9%), multifocal in 11 (61.1%); PVT in 8 (44.4%); comorbidities in 15 (83.3%). Only one patient presented side effects: ascites easily controlled with medications. Imaging evaluation at 3 months was performed in 17 patients. Complete response occurred in 9 (52.9%), partial response in 5 (29.4%), while progression was seen only in 3 cases (17.7%). One patient repeated TARE due to persistence of viable tumor, one underwent TACE in a non-targeted nodule and a third one a liver transplantation after successful down-staging. During a median clinical follow-up of 8 months, 6 patients died. Mortality was secondary to HCC progression in 4 of them: 3 died of hepatic failure and 1 of hepatorenal syndrome. The remaining 2 died of hepatic encefalophathy and heart failure. Median disease free survival and overall survival were respectively 13 and 16 months. Conclusions: TARE was a valid and safe treatment option in pa- tients with intermediate and advanced HCC stages. Low progression rate, good median survival and no severe adverse effects were seen in this group. TARE was a suitable procedure for elderly comorbid patients and also led to down-staging, potentially allowing liver transplantation. P.09.20 IS THE GUT THE FIRST PLAYER IN THE PROTECTIVE EFFECT OF COFFEE ON LIVER DAMAGE G. Mazzone 2 , P. Vitaglione 1 , V. Lembo 2 , G. D’Argenio 2 , A. Rossi *,2 , M. Guido 3 , M. Savoia 4 , N. Caporaso 2 , F. Morisco 2 1 Department of Agricultural Science, University of Naples Federico II, Portici, Italy; 2 Department of Clinical Medicine and Surgery, Gastroenterology Unit, University of Naples Federico II, Naples, Italy; 3 Department of Medicine, University of Padua, Padua, Italy; 4 Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy Background and aim: In the last two decades, various in vitro and in vivo studies evaluated the molecular determinants for the hep- atoprotective effects of coffee. We have previously demonstrated that liver damage induced by high fat diet (HFD) is reverted by coffee consumption thought a reduction of fat deposition in the liver and an amelioration of antioxidant and anti-inflammatory status. Nonetheless we hypothesize that the first target organ of coffee is the gut, supporting the protective effect on the liver by modulating the gut permeability and contributing to the concept of relevant role of gut-liver link. Material and methods: Three groups of C57BL/6 mice (n=8 each) were randomized into one of the following 12 week diets: 1) stan- dard diet (SD: 3.3 kcal/g, 5% fat); 2) high fat diet (HFD: 5.6 kcal/g, 58% fat); 3) HFD plus decaffeinated coffee solution (HFD+coffee) to a daily dosage corresponding to 6 cups of espresso coffee or 2 cups of filtered coffee for a 70 kg person. Hepatic histology was examined by H&E staining. Alanine-aminotrasferase (ALT), total cholesterol levels were measured in serum samples. Gene expression of PPAR-α and LXR-α was assessed in the liver. The expression of molecular